Recordati SpA - Company Profile
Powered by 
All the sales intelligence you need on Recordati SpA in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Recordati SpA fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Recordati SpA.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Recordati SpA (Recordati) is a pharmaceutical company that researches, develops, manufactures, and markets pharmaceuticals. The company offers pharmaceuticals for conditions related to cardiovascular, urology and uro-oncology, gastroenterological, cough and cold, metabolic, endocrinology, oncology and central nervous system, among others. It also offers cosmetics, dietary supplements, pregnancy test products, over-the-counter (OTC) and non-prescription pharmaceuticals, anti-infectives, and others. It also manufactures active pharmaceutical ingredients (APIs) and intermediates. The company sells its products directly in the countries of its operations and through licensees in other countries. Recordati is headquartered in Milan, Italy.
Headquarters
Italy
Address
Via Matteo Civitali, 1, Milan, 20148
Website
www.recordati.com
Telephone
39 02 487871
No of Employees
4,583
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
REC (BIT)
Revenue (2024)
$3.0B
11.8%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
6.5%
(2024 vs 2023)
Market Cap*
$12.2B
Net Profit Margin (2024)
XYZ
-4.8%
(2024 vs 2023)
* As of and is in US$
Recordati SpA premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pharmaceuticals | Phosphosoda |
| Active Pharmaceutical Ingredients (API) | Magnesio Supremo |
| Intermediates | Lomexin |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Contracts/Agreements | In December, the company signed an agreement to acquire the manufacturing and commercialization rights to Inrebic in Japan from Impact Biomedicines. |
| 2026 | Others | In March, the company to be acquired by CVC Capital Partners, a private equity and investment advisory firm. |
| 2025 | Contracts/Agreements | In June, the company signed a licensing and supply agreement with Amarin to commercialize the marketed cardiovascular medicine, Vazkepa (icosapent ethyl) across 59 countries. |
Competitor Comparison
| Key Parameters | Recordati SpA | UCB SA | Les Laboratoires Servier SAS | Ipsen SA | Chiesi Farmaceutici SpA |
|---|---|---|---|---|---|
| Headquarters | Italy | Belgium | France | France | Italy |
| City | Milan | Anderlecht | Suresnes | Boulogne-Billancourt | Parma |
| State/Province | - | Bruxelles-Capitale | - | Ile-de-France | Emilia-Romagna |
| No. of Employees | 4,583 | 10,117 | 20,000 | 5,358 | 7,686 |
| Entity Type | Public | Public | Private | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Andrea Recordati | Chairman | Executive Board | 2021 | 55 |
| Robert Koremans | Director; Chief Executive Officer | Executive Board | 2021 | 64 |
| Mike McClellan | Chief Financial Officer | Senior Management | 2026 | - |
| Bibianne Bon | Chief Legal Officer | Senior Management | 2023 | - |
| Alessandra Abate | Chief People Officer; Chief Culture Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer